Jefferies Group LLC Biomarin Pharmaceutical Inc Transaction History

Jefferies Group LLC

$10.2 Billion
Q3 2022

A detailed history of Jefferies Group LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Jefferies Group LLC holds 21,780 shares of BMRN stock, worth $1.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

21,780

Previous 2,434 794.82%

Holding current value

$1.2 Million

Previous $201,000 818.41%

% of portfolio

0.02%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Sep 21, 2023	BUY	$82.16 - $96.94 $1.59 Million - $1.88 Million	19,346 Added 794.82%	21,780 $1.85 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $1.45 Million - $1.71 Million	17,610 Added 422.3%	21,780 $1.85 Million
Q2 2022 Sep 21, 2023	SELL	$71.48 - $86.85 $451,467 - $548,544	-6,316 Reduced 72.18%	2,434 $201,000
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $509,509 - $619,066	-7,128 Reduced 63.09%	4,170 $200,000
Q1 2022 Sep 21, 2023	BUY	$74.28 - $92.69 $71,308 - $88,982	960 Added 12.32%	8,750 $674,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $260,574 - $325,156	3,508 Added 45.03%	11,298 $667,000
Q4 2021 Sep 21, 2023	SELL	$71.72 - $91.47 $1.12 Million - $1.42 Million	-15,557 Reduced 66.63%	7,790 $688,000
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $1.12 Million - $1.42 Million	-15,557 Reduced 66.63%	7,790 $688,000
Q3 2021 Sep 21, 2023	BUY	$74.77 - $85.47 $981,057 - $1.12 Million	13,121 Added 128.31%	23,347 $1.8 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $981,057 - $1.12 Million	13,121 Added 128.31%	23,347 $1.8 Million
Q2 2021 Sep 21, 2023	BUY	$75.51 - $84.79 $286,635 - $321,862	3,796 Added 59.04%	10,226 $853,000
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $286,635 - $321,862	3,796 Added 59.04%	10,226 $853,000
Q1 2021 Sep 21, 2023	SELL	$74.73 - $90.69 $1.32 Million - $1.6 Million	-17,663 Reduced 73.31%	6,430 $485,000
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $1.32 Million - $1.6 Million	-17,663 Reduced 73.31%	6,430 $486,000
Q4 2020 Sep 21, 2023	BUY	$72.61 - $90.2 $167,946 - $208,632	2,313 Added 10.62%	24,093 $2.11 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $1.74 Million - $2.16 Million	23,917 Added 13589.2%	24,093 $2.11 Million
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $1.88 Million - $3.43 Million	-26,146 Reduced 99.33%	176 $13,000
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $1.42 Million - $2.22 Million	17,889 Added 212.13%	26,322 $3.25 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $4.06 Million - $5.52 Million	-56,947 Reduced 87.1%	8,433 $713,000
Q4 2019 Feb 13, 2020	SELL	$64.27 - $86.37 $2.27 Million - $3.05 Million	-35,368 Reduced 35.11%	65,380 $5.53 Million
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $5.56 Million - $7.02 Million	82,426 Added 449.87%	100,748 $6.79 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $711,499 - $831,484	8,855 Added 93.54%	18,322 $1.57 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $2.64 Million - $3.1 Million	-31,405 Reduced 76.84%	9,467 $841,000
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $2.83 Million - $3.74 Million	-35,260 Reduced 46.31%	40,872 $3.48 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $578,453 - $651,129	6,159 Added 8.8%	76,132 $7.38 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $4.93 Million - $6.43 Million	64,909 Added 1281.77%	69,973 $6.59 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $4.81 Million - $5.74 Million	-61,947 Reduced 92.44%	5,064 $411,000
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $5.17 Million - $6.09 Million	63,988 Added 2116.71%	67,011 $5.98 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $243,653 - $287,033	3,023	3,023 $281,000

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Account

Jefferies Group LLC Biomarin Pharmaceutical Inc Transaction History